Duloxetine treatment for women with premenstrual dysphoric disorder: A single-blind trial

International Journal of Neuropsychopharmacology

Volumn 12, Issue 8, 2009, Pages 1081-1088

  Ramos, Melissa Guarieiro ^a,b   Hara, Cludia ^a   Rocha, Fbio Lopes ^a  

^a Instituto de Previdencia Dos Servidores do Estado de Minas Gerais IPSEMG   (Brazil)

^b NONE   (Brazil)

Author keywords

Clinical trial; Duloxetine; Premenstrual dysphoric disorder; Premenstrual syndrome; Treatment

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; APPETITE; ARTICLE; BLOOD PRESSURE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY RECORD OF SEVERITY OF PROBLEM; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LIBIDO; LIBIDO DISORDER; MENSTRUAL CYCLE; MORNING DOSAGE; NAUSEA; NIGHTMARE; OUTCOME ASSESSMENT; PILOT STUDY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SELF CONCEPT; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING; SYMPTOM; THERAPY EFFECT; THIRST; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; PILOT PROJECTS; PREMENSTRUAL SYNDROME; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; THIOPHENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69749096168     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709000066     Document Type: Article

References (36)

1. APA (2000). Diagnostic and Statistical Manual of Mental Disorders (4th edn, Text Revision). Washington DC: American Psychiatric Association.
2. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF (2005). Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. Journal of Psychiatric Research 39, 43-53.
3. Cohen LS, Miner C, Brown EW, Freeman E, Halbreich U, Sundell K, McCray S (2002). Premenstrual dailyfluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstetrics & Gynecology 100, 435-444. (Pubitemid 35246128)
4. Cohen LS, Soares CN, Lyster A, Cassano P, Brandes M, Leblanc GA (2004). Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology 24, 540-543.
5. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA (2002). Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. Journal of Clinical Psychiatry 63, 308-315. (Pubitemid 34456358)
6. Dimmock PW, Wyatt KM, Jones PW, O'Brien PM (2000). PMS Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 356, 1131-1136.
7. Endicott J, Nee J, Harrison W (2006). Daily Record of Severity of Problems (DRSP): reliability and validity. Archives of Womens Mental Health 9, 41-49.
8. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacology Bulletin 29, 321-326.
9. Freeman EW (2003). Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology 28 (Suppl. 3), 25-37.
10. Freeman EW (2004). Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs 18, 453-468.
11. Freeman EW (2005). Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder. Pharmacoeconomics 23, 433-444.
12. Freeman EW, Rickels K (1999). Characteristics of placebo responses in medical treatment of premenstrual syndrome. American Journal of Psychiatry 156, 1403-1408.
13. Freeman EW, Rickels K, Sondheimer SJ, Polansky M (1999). Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Archives of General Psychiatry 56, 932-939.
14. Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S (2004). Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. American Journal of Psychiatry 161, 343-351.
15. Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV (2001). Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstetrics & Gynecology 98, 737-744.
16. Guy W (1976). Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology (pp. 218-222). Washington, DC: US Dept Health, National Institute of Mental Health. Education and Welfare publication (ADM) 76-338.
17. Halbreich U, Bornstein J, Pearlstein T, Kahn LS (2003). The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28, 1-23.
18. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 23, 56-62.
19. Kirwin JL, Gören JL (2005). Duloxetine: a dual serotonin- norepinephrine reuptake inhibitor for treatment of major depressive disorder. Pharmacotherapy 25, 396-410.
20. Mazza M, Harnic D, Catalano V, Janiri L, Bria P (2008). Duloxetine for premenstrual dysphoric disorder: a pilot study. Expert Opinion in Pharmacotherapy 9, 517-521.
21. Parry BL (2001). The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications. CNS Drugs 15, 277-285.
22. Pearlstein T (2002). Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs 62, 1869-1885.
23. Pearlstein TB, Bellew KM, Endicott J, Steiner M (2005). Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double-blind, placebo-controlled trial. Primary Care Companion. Journal of Clinical Psychiatry 7, 53-60.
24. Pearlstein TB, Halbreich U, Batzar ED, Brown CS, Endicott J, Frank E, Freeman EW, Harrison WM, Haskett RF, Stout AL, Yonkers KA (2000). Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. Journal of Clinical Psychiatry 61, 101-109.
25. Ramos MG, Hara C, Rocha FL (2008). Duloxetine treatment of Premenstrual Dysphoric Disorder: case reports. Progress in Neuropsychopharmacology & Biological Psychiatry 32, 579-580.
26. Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borenstein J (2008). Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstetrics & Gynecology 111, 1175-1182.
27. Sheehan DV (2000). The Sheehan disability scale. In: Rush AJ, Pincus HA, First MB, Blacker D, Endicott J, Keith SJ (Eds.), Handbook of Psychiatric Measures (pp. 113-115). Washington DC: American Psychiatric Association.
28. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998). The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59 (Suppl. 20), 22-33.
29. Steiner M, Pearlstein T (2000). Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. Journal of Clinical Psychiatry 61 (Suppl. 12), 17-21. (Pubitemid 30796689)
30. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, Grover D, Streiner D (1995). Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/ Premenstrual Dysphoria Collaborative Study Group. New England Journal of Medicine 332, 1529-1534.
31. Sundblad C, Hedberg MA, Eriksson E (1993). Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 9, 133-145.
32. Sundblad C, Modigh K, Andersch B, Eriksson E (1992). Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatrica Scandinavica 85, 39-47.
33. Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, Eriksson E (1998). Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? Journal of Clinical Psychopharmacology 18, 390-398.
34. Wittchen HU, Becker E, Lieb R, Krause P (2002). Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychological Medicine 32, 119-132.
35. Wyatt KM, Dimmock PW, O'Brien PM (2002). Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews. Issue 4. Article no. CD001396.
36. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T, Severino S, Stout A, Stone A, Harrison W (1997). Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. Journal of the American Medical Association 278, 983-988.